Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns
and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective,
observational longitudinal study to evaluate the real world effectiveness and use of
prasugrel and other ADP receptor inhibitor therapies among myocardial infarction (MI)
participants treated with percutaneous coronary intervention (PCI) during the index
hospitalization. Participant management and treatment decisions are at the discretion of the
care team per routine clinical practice. Approximately 17,000 participants will be enrolled
at approximately 350 sites in the United States. Follow-up will be conducted through 15
months in approximately 15,650 participants.

TRANSLATE-ACS will complement the results of both randomized controlled clinical trials and
current registries in addressing the real world treatment patterns and clinical outcomes for
MI participants managed with PCI and initiated on ADP receptor inhibitor therapy. In
addition to determining the effectiveness of prasugrel in comparison to other ADP receptor
inhibitors, the study will also determine factors associated with initial ADP receptor
inhibitor selection and longitudinal patterns of use, evaluate the safety, and describe and
compare resource use and medical costs associated with ADP receptor inhibitors.
Additionally, this study will generate a continuum of information from the inpatient to
outpatient settings to provide a comprehensive picture of participant treatment and outcomes
not currently available for novel ADP receptor inhibitors.